Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture

doi:10.3748/wjg.v20.i43.16275

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 43

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6028)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

351

WORD

239

HTML

2537

Figures (1-4)

170

Tables (1-2)

189

Sum=3486

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1076

Download

1466

Sum=2542

Nov 21, 2014 (publication date) through Jul 28, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Nov 21, 2014; 20(43): 16275-16281
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16275

Table 2 Sorafenib toxicity grades based on common terminology criteria for adverse events version 4.0

Adverse events	Grade 1/2	Grade 3/4
Hand-foot skin reaction	3	1
Diarrhea	2	2
Hypertension	1	0
Skin rash	2	0
Anorexia	2	0
Mucositis	1	0
Agrypnia	1	0

Citation: Zheng SZ, Liu DJ, Sun P, Yu GS, Xu YT, Gong W, Liu J. Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture. World J Gastroenterol 2014; 20(43): 16275-16281
URL: https://www.wjgnet.com/1007-9327/full/v20/i43/16275.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i43.16275